Form D · Biotechnology
Genesis Therapeutics, Inc.
Burlingame, CA · CIK 0001775819
Offering snapshot reported Aug 25, 2023 · SEC filing
- Reported sold
- $224M Offering amount: $224M
- Investors reported
- 50 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2023 | Initial | $224,025,681 | No comparison | 50 | SEC filing |
| Dec 23, 2022 | Initial | $23,894,572 | No comparison | 33 | SEC filing |
| Dec 9, 2020 | Initial | $49,517,631 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-490705
Source: Form D, filed Aug 25, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leonard Bell | Director |
| Stephen Dann | Executive |
| Evan Feinberg | Director, Executive |
| Kris Jenner | Director |
| William Mccarthy | Executive |
| Vijay Pande | Director |
| Peptiboon Prasit | Director, Executive |
| Benjamin Sklaroff | Executive |
| Nicholas Stock | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1440 Chapin Ave Suite 385
Burlingame, CA, 94010
Burlingame, CA, 94010